**We Claim:**

1. A method of treating salt-sensitive hypertension in a mammal suffering therefrom, said method comprising the step of administering a therapeutically effective amount of a cyclic nucleotide phosphodiesterase (PDE) inhibitor to said mammal.

2. The method of Claim 1 wherein the PDE is a PDE that preferentially hydrolyzes cAMP.

3. The method of Claim 2 wherein the PDE is PDE4B or PDE4D or both PDE4B and PDE4D.

4. The method of claim 2 wherein the PDE is a renal isoform or splice variant of PDE4B and PDE4D.

5. The method of claim 2 wherein the PDE is PE4B1 or PDE4D5 or both PDE4B1 and PDE4D5.

6. The method of claim 1 wherein the inhibitor is an inhibitor of PDEs that preferentially hydrolyze cAMP.

7. The method of claim 6 wherein the inhibitor is an inhibitor of PDE4B or PDE4D or both PDE4B and PDE4D.

8. The method of claim 6 wherein the inhibitor is an inhibitor of renal isoforms and splice variants of PDE4B and PDE4D.

9. The method of claim 2 wherein the inhibitor is an inhibitor of PE4B1 or PDE4D5 or both PDE4B1 and PDE4D5.

10. The method of claim 6 wherein the PDE inhibitor is a 4-substituted – 2-pyrrolidinone.

11. The method of claim 10 wherein the PDE inhibitor is Rolipram (ZK-62711)

12. The method of claim 6 wherein the PDE inhibitor is Rolipram; 4-substituted – 2-pyrrolidinones; N-substituted cis-tetra-hydrophthalazinones; N-substituted cis-hexa-hydrophthalazinones; substituted aminopyridines; L-791943; TVX2706; RP73401 or RS25344.

13. The method of claims 1 - 12 wherein the mammal is human

14. A pharmaceutical composition for treating salt-sensitive hypertension, comprising a therapeutically-effective amount of a PDE inhibitor and a pharmaceutically-acceptable carrier, diluent ot adjuvant.

15. A pharmaceutical composition according to claim 14, wherein the PDE inhibitor is Rolipram; 4-substituted – 2-pyrrolidinones; N-substituted cis-tetra-hydrophthalazinones; N-substituted cis-hexa-hydrophthalazinones; substituted aminopyridines; L-791943; TVX2706; RP73401 or RS25344.

16. A pharmaceutical composition according to clam 14 wherein the PDE inhibitor inhibits PDE4B or PDE4D or both PDE4B and PDE4D.

17. A pharmaceutical composition according to claim 16 wherein the PDE inhibitor inhibits PE4B1 or PDE4D5 or both PDE4B1 and PDE4D5.